ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100) The combination demonstrated a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback